Abstract:ID 93958 Poster Board 481 A 3 adenosine receptor (AR) agonists are being developed for the treatment of autoimmune inflammatory diseases, chronic pain and cancer. A 3 AR agonists are not limited by cardiovascular side effects observed with other adenosine (A 1 and A 2A ) agonists that were in clinical trials. 2-Arylethynyl (North)-methanocarba adenosines have been explored as highly selective A 3 AR agonists, which is largely a function of the pseudoribose (bicyclic fused cyclopropane and cyclopentane) ring that pre-establishes a preferred (N) conformation for receptor recognition. Here, we compare analogues in the 5¢methylamide series having bulky C2-substitution, which either contain or lack an ethynyl spacer between adenine and a cyclic group. 2-Aryl compounds 11 , 13 , 14 , 19 , 22 , 23 , 27 , 29 , 31 and 34 , lacking an ethynyl spacer, displayed potent K i values of 2–30 nM at the human (h) A 3 AR, while other derivatives had greatly reduced affinity. The mouse (m) A 3 AR affinity was highly variable, with 2-arylethynyl groups greatly favoring high affinity ( 7 , 8 > 3c , 3d > 3b ) compared to 2-aryl analogues. However, 4¢truncated derivatives lacking a 2-ethynyl spacer had greatly reduced hA 3 AR affinity, even for those analogues containing affinity-enhancing N 6 -dopamine-derived substituents. This suggests that the 5¢methylamide group is especially important for anchoring these analogues in a deep hydrophilic subpocket in the receptor. hA 3 AR homology modeling indicated that 2-aryl and 2-arylethynyl groups have different conformations and receptor environments. The directly connected 2-aryl groups interact with ECL2 of the hA 3 AR, as opposed to the 2-arylethynyl groups, which interact with TM2. Functional assays of selected compounds in G protein-dependent and independent signaling were performed using engineered HEK293T cell lines. In a hA 3 AR miniG α i recruitment assay, 31 (MRS8062) was (slightly) more potent compared to a β-arrestin2 recruitment assay, and its maximal efficacy (E max ) was much higher (165%) than reference nonselective agonist NECA. Thus, in the 2-aryl series, A 3 AR affinity and selectivity were variable and generally reduced compared to the 2-arylethynyl series, with a greater dependence on the specific aryl group present. Selected compounds were protective in an vivo ischemic model of peripheral artery disease (PAD), in which other A 3 AR agonists demonstrated efficacy. Compounds 3a – 3c in the rigidified 2-arylethynyl series significantly decreased the % cell death in this model of skeletal muscle ischemia reperfusion injury/claudication, as previously shown only for moderately A 3 AR-selective ribosides or (N)-methanocarba derivatives (all lacking the 2-arylethynyl group). Thus, we have expanded A 3 AR agonist SAR for (N)-methanocarba adenosines and their application to skeletal muscle ischemia. NIDDK Intramural Res. ZIADK031117

Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists

Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A 3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary

Structural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization

Cryo-EM structures of adenosine receptor A3AR bound to selective agonists

Medicinal chemistry of adenosine A3 receptor ligands

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Discovery of Highly Potent Adenosine A1 Receptor Agonists: Targeting Positron Emission Tomography Probes.

Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers

Species dependence of A3 adenosine receptor pharmacology and function

Machine Learning for Discovery of New ADORA Modulators

Synthesis of Adenosine Analogues with Indole Moiety As Human Adenosine A3 Receptor Ligands.

Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes

ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor.

Structure−Activity Relationships of New 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as Allosteric Enhancers of the A<sub>3</sub>Adenosine Receptor

Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity

Methanocarba Analogues of Purine Nucleosides As Potent and Selective Adenosine Receptor Agonists.

Synthesis and biological evaluation of sugar-modified truncated carbanucleosides as A 2A and A 3 adenosine receptor ligands to explore conformational effect to the receptors